Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2012 Nov 11;5(1):150-4.
doi: 10.5539/gjhs.v5n1p150.

Comparison of superficial mycosis treatment using Butenafine and Bifonazole nitrate clinical efficacy

Affiliations
Randomized Controlled Trial

Comparison of superficial mycosis treatment using Butenafine and Bifonazole nitrate clinical efficacy

Mohammed A Abdul Bari. Glob J Health Sci. .

Abstract

Superficial fungal infections are commonly encountered by the physician. And the continuously changing epidemiology of invasive fungal infections results in the need for an expanded armamentarium of antifungal therapies. This study was designed to evaluate the safety and efficacy of Butenafine (BTF) versus Bifonazole (BFZ) in the treatment of superficial mycosis in a randomized, double-blind, parallel-group trial. Of 96 patients, 48 applied (BTF) cream and 48 applied (BFZ) cream for 2 weeks to tinea versicolor, corporis and cruris treat, while tinea of feet & hands was treated for 4 weeks duration. Efficacy was assessed after the end of treatment and 2 weeks later. At the end of therapy, we find somewhat more patients using (BTF) than using (BFZ) had a mycologic cure ((BTF), 87.5%; (BFZ) 83.3%) and effective clinical response ((BTF), 91.7%; (BFZ), 83.3%). (BTF) provides rapid and persistent antifungal activity and symptom relief in patients with superficial mycosis during treatment. And patients continued to improve for at least 2 weeks after treatment. The Rates of mycologic cure and effective treatment with (BTF) were higher than with (BFZ) at cessation of treatment and 2 weeks later. However, no significant difference found between the two drugs (p> 0.05).

PubMed Disclaimer

References

    1. Burns T, Breathnach S, Cox N, Griffiths C. Rook’s Textbook of Dermatology. 4th ed. 2004. http://dx.doi.org/10.1002/9780470750520 .
    1. Del Palacio A, Cuetara S, Perez A. Topical treatment of dermatophytosis and cutaneous candidosis with flutrimazole 1% cream: double-blind, randomized comparative trial with ketoconazole 2% cream. Mycoses. 1999;42:649–55. http://dx.doi.org/10.1046/j.1439-0507.1999.00520.x . - PubMed
    1. European Pharmacopoeia Commission. European Pharmacopoeia. 4th ed. 67075 Strasbourg Cedex, France: Council of Europe; 2001. p. 737.
    1. Fredriksson T. Treatment of dermatomycoses with topical tioconazole and miconazole. Dermatologica (Suppl) 1983;66:20–33. http://dx.doi.org/10.1159/000249910 . - PubMed
    1. Georgopapadakou N. H. Antifungals: mechanism of action and resistance, established and novel drugs. Curr. Opin. Mirobiol. 1998;1:547–557. http://dx.doi.org/10.1016/S1369-5274(98)80087-8 . - PubMed

Publication types

MeSH terms